Table I. Demographics of the study population
Early RA
ControlsAll RATreatment-NaiveTreated
Number of subjects, n (%)54a10046 (46)54 (54)
Age median, years (range)53 (21–91)56 (20–82)59 (20–82)54 (20–82)
Female/male (%)69/3161/3974/2650/50
RF positive, n (%)ND57 (57%)24 (42%)30 (58%)
ACCP positive, n (%)ND54 (54%)23 (44%)33 (56%)
ACCP concentration μ/ml, median (range)ND54 (0.1–411)57 (0.7–340)46.2 (0.1–411)
DAS28 median (range)NA4.6 (0.7–7.9)4.6 (2–.9)4.1 (0.7–7.1)
CRP median (range)NA9 (1–218)8 (1–92)9.5 (1–218)
ESR median (range)NA24 (1-81)24.5 (2–74)22.5 (1–81)
DMARDs, n (%)NA24 (24%)0 (0%)24 (44%)
Steroids, n (%)bNA25 (25%)0 (0%)25 (46%)
DMARDs and steroids, n (%)NA5 (5%)0 (0%)5 (10%)
  • DMARDs: methotrexate, hydroxychloroquine, sulfasalazine. Steroids: depo-medrone, prednisolone.

  • a 33 healthy, 19 osteoporosis, 2 osteoarthritis.

  • b 5–15 mg/day.

  • ACCP, anticyclic citrullinated peptide Ab; NA, not available; RF, rheumatoid factor.